DKSH Earnings Call Highlights Resilient Growth Momentum

DKSH Holding ((CH:DKSH)) has held its Q4 earnings call. Read on for the main highlights of the call.

DKSH’s latest earnings call struck an upbeat tone despite visible macro and currency headwinds. Management highlighted modest top-line growth, faster expanding core EBIT, strong free cash flow and disciplined capital returns, arguing that operational efficiency and Asia-focused strengths more than offset volatility in certain businesses and regions.

Revenue Growth and Acceleration

Net sales rose 2.9% at constant exchange rates to CHF 11.1 billion in 2025, with clear acceleration in the second half as growth stepped up to 3.6%. Organic net sales advanced 2.5% for the year, improving from 2.1% in the first half to 3.6% in the back half, suggesting momentum is building into 2026.

Core EBIT Expansion

Core EBIT increased 6.7% year-on-year to CHF 349 million, comfortably outpacing sales and lifting the core EBIT margin from 3.1% to 3.2%. Organic core EBIT grew 5%, roughly double the rate of organic net sales, underscoring DKSH’s improving profitability and operating leverage.

Very Strong Cash Generation

Free cash flow reached CHF 215.5 million, underpinned by cash conversion of 95.2% and marking a sixth straight year above the 90% target. This robust cash generation left the group in a positive net cash position and enabled disciplined capital allocation without stretching the balance sheet.

Accelerated M&A Activity and Capital Return

The group announced nine accretive deals in 2025, bringing total acquisitions since 2019 to 35 compared with 16 in the prior seven-year period. Reflecting confidence in recurring cash flows, the board proposed lifting the ordinary dividend by 6.4% to CHF 2.50 per share, the 13th consecutive annual increase.

Healthcare Business Outperformance

Healthcare, DKSH’s largest unit, grew net sales 4.6% to CHF 5.8 billion and lifted core EBIT to CHF 174.2 million with a 3% margin. This marked a fourth straight year of margin expansion, helped by a rising share of higher-value commercial outsourcing services, which now account for 55% of the segment.

Consumer Goods Recovery in H2

Consumer Goods delivered only 1.2% net sales growth for the full year but showed a marked second-half rebound with 2.8% growth. Core EBIT rose 5.4% to CHF 89.7 million, with about 10 basis points of margin expansion and roughly 14% core EBIT growth in the last six months, driving an H2 margin near 3%.

Performance Materials Resilience in Asia

Performance Materials increased net sales 1.4% to CHF 1.4 billion, with Asia Pacific, about 60% of sales, advancing a solid 5.5%. Core EBIT rose 1.9% and margin improved to 8.2%, while core EBITA reached CHF 120.4 million with an 8.9% margin, supported by firm pricing and three bolt-on acquisitions.

Technology BU Strategic Moves and Digital Growth

The Technology unit posted results roughly in line with 2024 amid macro softness and delayed customer spending but used the period to reshape its portfolio. It completed five Scientific Solutions acquisitions, exited non-core cable activities and saw strong growth in digital sales channels, positioning the business for a cyclical upturn.

Operational Efficiency and Cost Savings

DKSH continued to extract efficiencies from its asset-light model, cutting logistics and distribution costs by about CHF 35 million over five years. These measures contributed around 30 basis points to core EBIT margin improvement, while low capex of 0.3%–0.5% of sales and optimized working capital reinforced high returns on invested capital.

Multi-year Financial Improvements

Over the past five years, net sales have compounded at 4.2% annually, while core EBIT has grown at a faster 11.6% pace. Core conversion rose to 21.4%, core EBIT margin expanded by 60 basis points to 3.2%, and core ROE improved to 12.4% with an equity ratio of 33.1%, highlighting steadily improving financial quality.

Currency Headwinds

The appreciation of the Swiss franc weighed significantly on reported figures, reducing net sales by 3.1% and core EBIT by 5% versus constant-currency levels. Management emphasized that underlying operational performance was therefore stronger than headline numbers might suggest, especially in faster-growing Asian markets.

Macroeconomic Uncertainty and H1 Weakness

Global macro uncertainty, particularly in the first half of 2025, created a subdued demand backdrop and delayed customer investments. This muted early-year topline momentum and left DKSH more reliant on efficiency gains and mix improvements before growth improved in the second half.

Technology BU Investment Delays

Within the Technology business, customers’ delayed capex and investment decisions constrained growth, limiting performance to roughly flat versus 2024 levels. Management framed this as a timing issue rather than a structural problem, signalling expectations for a more visible recovery from 2026 onwards.

Performance Materials Volatility and Tariff Concerns

Performance Materials endured a “rocky” 2025 with pronounced quarter-to-quarter swings, including a weak second quarter followed by a strong third-quarter rebound. Tariff-related disruptions and ongoing weakness in industrial end markets added uncertainty and competitive pressure, although Asia helped cushion the impact.

Modest Consumer Goods Growth and Market Exit

Despite its second-half improvement, Consumer Goods managed only modest 1.2% net sales growth for the year as a whole. The decision to exit Indonesia reduced the unit’s footprint in that market, though acquired businesses helped offset some of the resulting drag on performance.

Selective Own-brands Headwinds

Some own-brand products in the Healthcare division underperformed, particularly in markets like Myanmar that faced local weakness. This tempered the incremental EBIT contribution from the own-brands portfolio, even as the broader Healthcare business continued to grow and improve its margins.

One-off and Non-core Costs

Non-core items, including USD 7 million of restructuring charges, CHF 3.9 million of project costs and CHF 1.8 million related to trademark license disposals, weighed on reported profit. These one-offs mask some of the underlying operational progress but were positioned as necessary steps in the group’s ongoing transformation.

Volatile M&A Market

Management disclosed that several larger potential deals were explored in 2025 but ultimately did not close, underscoring volatility in the M&A landscape. Even so, the company maintains an active pipeline and sees further acquisition opportunities as likely, given its financial flexibility and strategic focus.

2026 Outlook and Guidance

For 2026, DKSH offered cautious but positive guidance, expecting core EBIT to exceed the CHF 349 million achieved in 2025 and reaffirming a midterm plan to lift margins by at least 10 basis points per year. Closed deals are expected to add about 0.8% to net sales, with further upside from additional M&A, while management plans modest capex, maintains a progressive dividend and anticipates only a slight FX drag.

DKSH’s earnings call painted a picture of a company steadily compounding value through disciplined execution, sharp cost control and selective deal-making. While FX, macro uncertainty and sector volatility remain watchpoints, the firm’s strong cash generation, growing Healthcare and Asia franchises and measured 2026 guidance are likely to appeal to long-term investors focused on resilience and gradual margin expansion.